Structural basis of development of multi-epitope vaccine against middle east respiratory syndrome using in silico approach

Infection and Drug Resistance

Volumn 11, Issue , 2018, Pages 2377-2391

  Srivastava, Sukrit ^a,b   Kamthania, Mohit ^a,c   Singh, Soni ^a   Saxena, Ajay K ^b   Sharma, Nishi ^a  

^a MANGALAYATAN UNIVERSITY   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c Institute of Applied Medicines and Research   (India)

Author keywords

Epitope; Human transporter associated with antigen processing; Immunoinformatics; MD simulation; MERS; MERS CoV; Middle east respiratory syndrome; Middle east respiratory syndrome coronavirus; Molecular docking; Molecular dynamics simulation; Multi epitope vaccine; TAP; TLR 3; Toll like receptor 3

Indexed keywords

BETA DEFENSIN 2; BETA DEFENSIN 3; COMPLEMENTARY DNA; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN; IMMUNOLOGICAL ADJUVANT; MIDDLE EAST RESPIRATORY SYNDROME MULTI EPITOPE VACCINE; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIGEN BINDING CELL; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEX FORMATION; COMPUTER MODEL; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG SCREENING; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; STRUCTURAL MODEL;

EID: 85057620981     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S175114     Document Type: Article

References (70)

1. WHO MERS-CoV Global Summary and Risk Assessment. 2016. Available from: www.who.int/emergencies/mers-cov/mers-summary-2016. pdf. Accessed May 20, 2018.
2. Assiri A, McGeer A, Perl TM, et al; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med Overseas Ed. 2013;369(5):407–416.
3. Oboho IK, Tomczyk SM, Al-Asmari AM, et al. 2014 MERS-CoV outbreak in Jeddah – a link to health care facilities. N Engl J Med. 2015;372(9):846–854.
4. Park JW, Lee KJ, Lee KH, et al. Hospital Outbreaks of Middle East Respiratory Syndrome, Daejeon, South Korea, 2015. Emerg Infect Dis. 2017;23(6):898–905.
5. Kim KM, Ki M, Cho SI, et al. Epidemiologic features of the first MERS outbreak in Korea: focus on Pyeongtaek St. Mary’s Hospital. Epidemiol Health. 2015;37:e2015041.
6. Ki M. 2015 MERS outbreak in Korea: hospital-to-hospital transmission. Epidemiol Health. 2015;37:e2015033.
7. World Health Organization. Emergencies Preparedness, Reponse: Coronavirus Infections [cited October 25, 2015]. Available from: http://www.who.int/csr/don/25-october-2015-mers-korea/en/. Accessed May 20, 2018.
8. Wang L, Shi W, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712.
9. Xie Q, He X, Yang F, et al. Analysis of the genome sequence and prediction of B-cell epitopes of the envelope protein of Middle East respiratory syndrome-coronavirus. IEEE/ACM Trans Comput Biol Bioinform. 2018;15(4):1344–1350.
10. Wang YS, Chang CK, Hou MH. Crystallographic analysis of the N-terminal domain of Middle East respiratory syndrome coronavirus nucleocapsid protein. Acta Crystallogr F Struct Biol Commun. 2015;71(Pt 8):977–980.
11. Lui PY, Wong LY, Fung CL, et al. Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerg Microbes Infect. 2016;5(4):e39.
12. Menachery VD, Mitchell HD, Cockrell AS, et al. MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis. MBio. 2017;8(4):e00665-17.
13. Lei J, Mesters JR, Drosten C, Anemüller S, Ma Q, Hilgenfeld R. Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features. Antiviral Res. 2014;109:72–82.
14. Tomar S, Johnston ML, St John SE, et al. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. J Biol Chem. 2015;290(32):19403–19422.
15. Lei J, Hilgenfeld R. Structural and mutational analysis of the interaction between the Middle-East respiratory syndrome coronavirus (MERS-CoV) papain-like protease and human ubiquitin. Virol Sin. 2016;31(4):288–299.
16. Lu R, Zou L, Wang Y, et al. Sequencing and Phylogenetic Analyses of Structural and Accessory Proteins of Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China, 2015. Bing Du Xue Bao. 2015;31(4):333–340. Chinese.
17. Wilson SS, Wiens ME, Smith JG. Antiviral mechanisms of human defensins. J Mol Biol. 2013;425(24):4965–4980.
18. Duits LA, Nibbering PH, van Strijen E, et al. Rhinovirus increases human β-defensin-2 and-3 mRNA expression in cultured bronchial epithelial cells. Pathogens and Disease. 2003;38(1):59–64.
19. Antoniou AN, Powis SJ, Elliott T. Assembly and export of MHC class I peptide ligands. Curr Opin Immunol. 2003;15(1):75–81.
20. Delneste Y, Beauvillain C, Jeannin P. Innate immunity: structure and function of TLRs. Med Sci (Paris). 2007;23(1):67–73.
21. Totura AL, Whitmore A, Agnihothram S, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. MBio. 2015;6(3):e00638-15.
22. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22(2):195–201.
23. Tenzer S, Peters B, Bulik S, et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci. 2005;62(9):1025–1037.
24. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhütter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol. 2003;171(4):1741–1749.
25. Hoof I, Peters B, Sidney J, et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2009;61(1):1–13.
26. Calis JJ, Maybeno M, Greenbaum JA, et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013;9(10):e1003266.
27. Wang P, Sidney J, Kim Y, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010;11(1):568.
28. Sidney J, Assarsson E, Moore C, et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 2008;4(1):2.
29. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 2007;8(1):238.
30. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol. 1999;17(6):555–561.
31. Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics. 2006;7:153.
32. Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2:2.
33. Chou PY, Fasman GD. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol. 1978;47:45–148.
34. Emini EA, Hughes JV, Perlow DS, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol. 1985;55(3):836–839.
35. Karplus PA, Schulz GE. Prediction of chain flexibility in proteins. Naturwissenschaften. 1985;72(4):212–213.
36. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990;276(1–2):172–174.
37. Parker JM, Guo D, Hodges RS. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry. 1986;25(19):5425–5432.
38. Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 2012;8(12):e1002829.
39. Ponomarenko J, Bui HH, Li W, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008;9:514.
40. Bui HH, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics. 2007;8:361.
41. Gupta S, Kapoor P, Chaudhary K, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8(9):e73957.
42. Sievers F, Wilm A, Dineen D, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011;7:539.
43. Benkert P, Tosatto SC, Schomburg D. QMEAN: A comprehensive scoring function for model quality assessment. Proteins. 2008;71(1):261–277.
44. Singh S, Singh H, Tuknait A, et al. PEPstrMOD: structure prediction of peptides containing natural, non-natural and modified residues. Biol Direct. 2015;10:73.
45. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–2791.
46. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.
47. Abraham MJ, Murtola T, Schulz R, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2(2):19–25.
48. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc. 1996;118(45):11225–11236.
49. Oldham ML, Grigorieff N, Chen J. Structure of the transporter associated with antigen processing trapped by herpes simplex virus. Elife. 2016;5:e21829.
50. Hu W, Li F, Yang X, et al. A flexible peptide linker enhances the immunoreactivity of two copies HBsAg preS1 (21-47) fusion protein. J Biotechnol. 2004;107(1):83–90.
51. Hoover DM, Rajashankar KR, Blumenthal R, et al. The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem. 2000;275(42):32911–32918.
52. Hajighahramani N, Nezafat N, Eslami M, Negahdaripour M, Rahma-tabadi SS, Ghasemi Y. Immunoinformatics analysis and in silico designing of a novel multi-epitope peptide vaccine against Staphylococcus aureus. Infect Genet Evol. 2017;48:83–94.
53. Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013;65(10):1357–1369.
54. Nagpal G, Gupta S, Chaudhary K, Dhanda SK, Prakash S, Raghava GP. Vaccine DA: Prediction, design and genome-wide screening of oligodeoxynucleotide-based vaccine adjuvants. Sci Rep. 2015;5:12478.
55. Dhanda SK, Vir P, Raghava GP. Designing of interferon-gamma inducing MHC class-II binders. Biol Direct. 2013;8:30.
56. Saha S, Raghava GP. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006;34(Web Server issue):W202–W209.
57. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8:4.
58. Gasteiger E, Hoogland C, Gattiker A, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The Proteomics Protocols Handbook. Chicago, IL: Humana Press; 2005:571–607.
59. Källberg M, Wang H, Wang S, et al. Template-based protein structure modeling using the RaptorX web server. Nat Protoc. 2012;7(8):1511–1522.
60. Ko J, Park H, Heo L, Seok C. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res. 2012;40(Web Server issue):W294–W297. Available from: http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE. Accessed October 17, 2018.
61. Lovell SC, Davis IW, Arendall WB 3rd, et al. Structure validation by Cal-pha geometry: phi,psi and Cbeta deviation. Proteins. 2003;50(3):437–450.
62. Bell JK, Botos I, Hall PR, et al. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci U S A. 2005;102(31):10976–10980.
63. Duhovny D, Nussinov R, Wolfson HJ. Efficient unbound docking of rigid molecules. In: Guigó R, Gusfield D, editors. Proceedings of the 2’nd Workshop on Algorithms in Bioinformatics (WABI). Vol. 2452. Rome: Lecture Notes in Computer Science; 2002:185–200.
64. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33(Web Server issue):W363–W367.
65. Nezafat N, Eslami M, Negahdaripour M, Rahbar MR, Ghasemi Y. Designing an efficient multi-epitope oral vaccine against Helicobacter pylori using immunoinformatics and structural vaccinology approaches. Mol Biosyst. 2017;13(4):699–713.
66. Morla S, Makhija A, Kumar S. Synonymous codon usage pattern in glycoprotein gene of rabies virus. Gene. 2016;584(1):1–6.
67. Wu X, Wu S, Li D, et al. Computational identification of rare codons of Escherichia coli based on codon pairs preference. BMC Bioinformatics. 2010;11(1):61.
68. Zhao J, Alshukairi AN, Baharoon SA, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol. 2017;2(14):eaan5393.
69. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic acids research. 2014:43(D1); D423–D431.
70. Xu D and Zhang Y. Improving the Physical Realism and Structural Accuracy of Protein Models by a Two-step Atomic-level Energy Mini-mization. Biophys J. 2011;101(10):2525–34.